Your browser doesn't support javascript.
loading
The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.
Barrett, A John; Ito, Sawa.
Afiliação
  • Barrett AJ; Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Ito S; Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Blood ; 125(21): 3230-5, 2015 May 21.
Article em En | MEDLINE | ID: mdl-25852053
The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell transplantation (SCT). Nevertheless, SCT still remains an option for accelerated/blastic-phase and selected chronic-phase CML. Transplant outcomes can be optimized by peritransplant TKIs, conditioning regimen, BCR-ABL monitoring, and relapse management. Controversies exist in transplant timing, pediatric CML, alternative donors, and economics. SCT continues to serve as a platform of "operational cure" for CML with TKIs and immunotherapies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Transplante de Células-Tronco Hematopoéticas Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Transplante de Células-Tronco Hematopoéticas Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article